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Abstract 
Aims/hypothesis. The relation between insulin secretion and the incidence of hypertension has not 
been well characterized. We hypothesised that both a parental history of diabetes and the TCF7L2 
polymorphism, which increases susceptibility todiabetesbecause of impaired beta cell function, are 
associated with incident hypertension. We assessed in a separate cohort whether low insulin 
secretion is related to incident hypertension. 
Methods Nine-year incident hypertensionwas studied in 2391 normotensive participants from the 
D.E.S.I.R. cohort.The relation between insulin secretion and 3-year incident hypertension was 
investigated in 1047 non-diabetic, normotensive individuals from the RISC cohort. Insulin secretion 
during an OGTT was expressed in relation to the degree of insulin resistance, as assessed by a 
hyperinsulinemic-euglycemic clamp. 
Results In the D.E.S.I.R. cohort, a parental history of diabetes and the TCF7L2 at-risk variant were 
both associated with hypertension incidence at year-9, independently of waist, blood pressure, 
fasting glucose, insulin levels and the HOMA-IR at inclusion (p=0.02 for parental history, p=0.006 
for TCF7L2). In the RISC cohort, a lower insulin secretion rate during the OGTT at baseline was 
associated with both higher blood pressure and a greater risk of hypertension at year-3. This inverse 
correlationbetween the insulin secretion rate and incident hypertension persisted after controlling 
for baseline insulin resistance, glycaemia and blood pressureat baseline (p=0.007). 
Conclusions/interpretationParental history of diabetes, the TCF7L2polymorphism and a reduced 
insulin secretion rate were consistently associated with incident hypertension. A low insulin 
secretion rate may be a new risk factor for incident hypertension, beyond insulin resistance. 
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Abbreviations:  
D.E.S.I.R.: Data from an Epidemiological Study on the Insulin Resistance syndrome 
HOMA2-IR: HOMA of insulin resistance 
HOMA2%B: HOMA of beta cell function 
OGTT: Oral glucose tolerance test 
RISC: Relationship between Insulin Sensitivity and Cardiovascular disease  
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Introduction 
Hypertension and type 2 diabetes are strongly interrelated and may share common environmental 
risk factors such as sedentary behaviours, visceral adiposity and insulin resistance[1]. Elevated 
blood pressure confers an increased risk for incident type 2 diabetes in the general population [2] 
and hypertension treatments may also modulate the risk of diabetes [3]. Fasting blood glucose, 
hyperinsulinemia and HbA1c have been associated with the development of hypertension in non-
diabetic individuals [4-8]. However, the pathophysiology underlying the association between 
elevated glycemia and incident hypertension has not been well characterized. In particular, the 
impact on incident hypertension of a parental history of diabetes or genetic predisposition to type 2 
diabetes, which is mainly associated with beta cell dysfunction [9], is not known. Furthermore, 
although the epidemiological link between insulin resistance and hypertension is recognized, the 
relation between insulin secretion and the incidence of hypertension and elevated blood pressure 
has not been investigated in the general population. 
The aim of our study was to assess in the prospective D.E.S.I.R. cohort, the impact of a 
genetic predisposition to type 2 diabetes, on the development of hypertension. We analyzedthe 
impact of the TCF7L2 polymorphismon incident hypertension, because this polymorphism has the 
largest effect on susceptibility to diabetes among the predisposing genes discovered to date [10]. As 
we observed an association with the TCF7L2 at-risk allele, we tested whether defects in insulin 
secretion predispose to 3-year incident hypertension, in 1047 non-hypertensive, non-diabetic 
participants from the RISC cohort, all of whom had an accurate evaluation at baseline of both 
insulin sensitivity by the hyperinsulinaemic-euglycaemic clamp and insulin secretion from an 
extended OGTT [11]. 
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Research Design and Methods 
The D.E.S.I.R. cohort 
We studied men and women aged 30–65 years, who participated in the 9-year follow-up study, Data 
from an Epidemiological Study on the Insulin Resistance Syndrome (D.E.S.I.R.). Participants were 
recruited from volunteers offered periodic health examinations free of charge by the French Social 
Security, in 10 health examinations centres in western France[12, 13]. All signed an informed 
consent and the protocol was approved by an ethics committee.Cases of hypertension were defined 
by treatment for hypertension or resting blood pressure ≥ 140 (systolic) or ≥ 90 (diastolic) mmHg at 
one of the four three-yearly examinations. After exclusion of individuals with hypertension at 
baseline, we studied 2391 participants with genotype data for TCF7L2 (745 had incident 
hypertension during the follow-up).  
 
Clinical assessment  
Two measures of blood pressure, using a mercury sphygmomanometer, were taken in a supine 
position after 5 minutes rest; mean values were used. Weight and height were measured in lightly 
clad participants, and body mass index (BMI) calculated. The examining physician noted the 
parental history of diabetes in a clinical questionnaire; treatment for diabetes and hypertension were 
recorded at each of the three yearly examinations.Smoking habits and alcohol intake were recorded 
in an auto-questionnaire. 
 
Biochemical measurements 
All biochemical measurements were from one of four health center laboratories located in France at 
Blois, Chartres, La Riche, and Orléans. The interlaboratory variability for normal and pathological 
values was assessed monthly. Fasting plasma glucose, measured by the glucose-oxidase method, 
was applied to fluorooxalated plasma using a Technicon RA100 analyzer (Bayer Diagnostics, 
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Puteaux, France) or a Specific or a Delta device (Konelab, Evry, France). HbA1c was determined by 
high-performance liquid chromatography (L9100 ion-exchange analyzer; Hitachi/Merck-VWR, 
Fontenay-sous-Bois, France) or an immunoassay (DCA 2000; Bayer Diagnostics). Insulin was 
quantified by microparticle enzyme immunoassay with an automated analyzer (IMX; Abbott, 
Rungis, France). Glucose, HbA1c and insulin have been standardized over laboratories and over the 
years of the study. Indexes of insulin resistance (HOMA2-IR) [14] and beta cell secretion 
(HOMA2%B) were computed using software downloaded at http://www.dtu.ox.ac.uk[15]. 
 
Genotyping 
TCF7L2 single nucleotide polymorphism (SNP) rs7903146 genotyping was performed with the 
SNPlex™ Technology (Applied Biosystems, Foster City, CA) based on the Oligonucleotide 
Ligation Assay (OLA) combined with multiplex PCR target amplification 
(http://www.appliedbiosystems.com) [12]. 
 
The RISC cohort 
RISC is a prospective observational cohort study whose rationale and methodology have been 
published, as well as the characteristics of the individuals recruited[11, 16]. Clinically healthy men 
and women, aged 30-60 years, were recruited from the local populations of 19 centres in 14 
European countries. Initial exclusion criteria were: treatment for obesity, hypertension, lipid 
disorders or diabetes, pregnancy, cardiovascular or chronic lung disease, weight change ≥5 kg in the 
last 6 months, cancer (in the last 5 years) and renal failure. Exclusion criteria after screening were: 
arterial blood pressure ≥140/90 mmHg, fasting plasma glucose ≥7.0 mmol/l, 2-hour plasma glucose 
(following a 75-g OGTT) ≥11.0 mmol/l, total serum cholesterol ≥7.8 mmol/l, serum triacylglycerol 
≥4.6 mmol/l, and ECG abnormalities. We studied 1,047 healthy individuals (579 women and 468 
men) who had an evaluation of both insulin sensitivity and insulin secretion at baseline and who 
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had complete data at the three years follow up. Ethics Committee approval was obtained by each 
recruiting centre. Volunteers were given detailed written information on the study as well as an oral 
explanation, and they all signed a consent form.  
Height and body weight were measured and BMI calculated.Alcohol and tobacco 
consumption was assessed using a standardized semi-quantitative questionnaire [17].Information on 
physical activity was collected with the 7-day International Physical Activity Questionnaire 
(IPAQ), a previously validated assessment tool for international studies, that provides a 
comprehensive evaluation of daily physical activity habits [18].   
 
Blood Pressure 
Blood pressure was measured in triplicateafter five minutes of rest, by trained study nurses using an 
OMRON 705CP (Omron Healthcare GmbH, Hamburg, Germany) with participants sitting, 
according to a standard protocol; the median of these readings was used in this analysis for both the 
baseline and the follow-up examinations. Hypertension was defined as median systolic blood 
pressure ≥ 140 mmHg and/or median diastolic blood pressure ≥ 90 mmHg or treatment for 
hypertension in routine care at follow-up.   
 
OGTT 
Blood samples were taken at fasting and 30, 60, 90 and 120 min into the OGTT, for central analysis 
of routine blood chemistry. Blood collected during the studies was separated into plasma and 
serum, aliquoted and stored at -20 ºC for central assays of glucose and insulin. 
Glucose concentrations were measured by the glucose oxidase technique. Plasma insulin and 
C-peptide were measured by a two-site time-resolved fluoroimmunoassay (AutoDELFIA Insulin 
kit; Wallac Oy, Turku, Finland) using monoclonal antibodies, with the following assay 
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characteristics (for insulin and C-peptide, respectively): sensitivity 1–2 and 5 pmol/l, within-assay 
variation 5 and 5% and between-assay variation 5 and 3.5%.  
 
Insulin sensitivity 
On a separate day within one month of the OGTT, participants had a hyperinsulinemic-euglycaemic 
clamp. Exogenous insulin was administered as a primed-continuous infusion at a rate of 
240 pmol.min-1.m-2 with a variable 20% dextrose infusion adjusted every 5-10 min to maintain 
plasma glucose level within 0.8 mmol/l (±15%) of the target glucose level (4.5-5.5 mmol/l). The 
clamp procedure was standardised across centres[11]; the data from each clamp study were 
transferred to the coordinating centre, where they underwent quality control scrutiny according to 
pre-set criteria. 
 Insulin sensitivity is expressed as the ratio of the M value during the final 40 min of the 2 h 
clamp, to the mean plasma insulin concentration measured during the same interval (M/I), 
normalised to fat-free mass and expressed in units of µmol.min-1.kg-fat-free-mass–1(nmol.l-1)-1. 
 
Insulin secretion 
Beta-cell function was assessed from the OGTT using a model describing the relationship between 
insulin secretion (calculated from C-peptide with the method of van Cauter et al [19]and glucose 
concentration, previously described in detail[20, 21]. From the model-estimated beta-cell dose-
response, relating insulin secretion (in pmol.min−1.m−2) to glucose concentration, insulin secretion 
at 5 mmol/l glucose (the average basal glucose in the subjects with normal glucose tolerance) was 
estimated. This parameter represents insulin secretion in basal conditions, if basal glucose were 
5 mmol/l in each participant. Total insulin secretion was also determined using the model(integral 
during the OGTT, in nmol.m-2)[21].  We considered, for all statistical analyses, that the product of 
either total insulin secretion or insulin secretion at 5 mmol/l glucose with the M/I value from the 
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The data are expressed as mean ± SDor as median (interquartile range) for variables with a skewed 
distribution, and categorical data as percentages. Variables that were not symmetrically distributed 
were log transformed before analyses. Baseline characteristics, means and percentages, were 
compared using Student’s t and χ² tests respectively, according to incident hypertension.  
For the D.E.S.I.R. cohort, as there was no significant interaction between sex and either 
parental history of diabetes or the TCF7L2 genotype on the risk of hypertension, we analysed men 
and women together. The relations between both parental diabetes and the TCF7L2 genotype with 
incident hypertension were assessed by logistic regression analysis, with adjustment for gender, age 
and waist circumference. Further adjustments for fasting insulinemia, fasting glycemia and mean 
blood pressure were made. We also tested for an interaction between HbA1c> 5.7% and TCF7L2 
variants on incident hypertension.  
In the RISC cohort, blood pressure levels at year 3 were compared according to the quartiles 
of insulin secretion rate at baseline by ANOVA; we excluded individuals treated by 
antihypertensive medications at year 3 for this analysis. 
A logistic regression analysis was used to test the association between the insulin secretion 
rate at baseline, assessed both as a continuous variable and stratified into quartiles, and incident 
hypertension at year-3 with adjustment for age, gender, recruitment centre, physical activity, waist, 
fasting glycaemia, systolic and diastolic blood pressure levels at baseline. 
Statistical analyses used StatView (version 5.0, SAS Institute Inc.,NC) and SAS version 9.2 
(SAS Institute, Cary, NC).  




The D.E.S.I.R. cohort 
In the D.E.S.I.R. cohort,those with incident hypertension had higher fasting glucose, HbA1c, waist 
circumference, and insulin concentrations at baseline as compared to those who remained 
normotensive (Table 1). 
Fasting glycaemia but not HbA1c levels at baseline remained associated with incident 
hypertension in a logistic regression analysis, after adjustment for gender and baseline age, waist 
circumference, and mean blood pressure. Neither HOMA2-IR nor the HOMA2%B indices were 
significantly related to the risk of incident hypertension in this multivariable model. 
 
Parental history of diabetes 
A parental history of diabetes was associated with a higher incidence of hypertension at 9 years 
(36% vs 30%, p=0.02). This association persisted after controlling for potential confounders such as 
waist circumference and BMI (Table 2).Further adjustment for baseline fasting glycaemia, fasting 
insulinaemia, HOMA2-IR andHOMA2%B did not alter the significant relationship (Table 2). 
 
TCF7L2 genotype 
The TCF7L2 variant conformed to Hardy-Weinberg equilibrium. Blood pressure levels at baseline 
did not differ according to the TCF7L2 genotype. However, TCF7L2 at-risk variants (CT + TT) 
were significantly associated with both higher systolic and diastolic blood pressure at year 9 in 
univariate analysis [CT+TT vs CC genotype: 137 ± 19 vs 135 ± 19 mmHg, p=0.02 for systolic; 81 
± 10 vs 80 ± 10 mmHg, p=0.01 for diastolic blood pressure]. 
The presence of the T allele was associated with an increased risk of incident hypertension 
at year-9, after controlling for gender and age, and the association persisted after further adjustment 
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for waist circumference, BMI, mean blood pressure, fasting glycaemia, insulinaemia, HOMA2-IR 
andHOMA2%B at baseline (Table 3). 
We further assessed whether baseline BMI or glycaemic status modified the effect of 
TCF7L2 at-risk allele on the risk of incident hypertension. There was no significant interaction 
between BMI (≥ or <27 kg/m2) and TCF7L2 on incident hypertension (pinteraction=0.25). However, 
there was a significant interaction between baseline HbA1c above the median value (≥5.7%) and the 
effect of TCF7L2 polymorphism on incident hypertension (pinteraction=0.03). The risk of 
hypertension after controlling for gender, age and waist circumference was greater for individuals 
who carried the T allele with HbA1c ≥5.7% at baseline [OR: 1.82;95% CI (1.21, 2.74), p=0.004] 
than for those with the T allele but normal HbA1c< 5.7% [1.11(0.90, 1.37), p=0.3].  
 
The RISC cohort 
Baseline glycaemia and hypertension at year 3 
In univariate analysis, both fasting and 2hr glycaemia at baseline were significantly associated with 
incident hypertension at year-3 (Table 4). However, in a multivariable analysis, the association 
between both fasting glycaemia [OR: 1.34; 95% CI (0.96, 1.86); p=0.09] and 2hr glycaemia [1.03; 
(0.92, 1.16); p=0.63] with the risk of hypertension at year-3 was no longer significant after 
controlling for gender, age, recruitment center and waist circumference respectively. 
 
Baseline insulin secretion and hypertension at year 3 
Individuals who developed hypertension at year-3 had at baseline, a reduced total insulin secretion 
during the OGTT and also a reduced basal beta-cell function at 5 mmol/l glucose, as compared to 
those who remained normotensive (Table 4). This suggests that individuals with subtle alterations 
in insulin secretion, after accounting for the concomitant degree of insulin resistance, were at higher 
risk of developing hypertension at follow-up.  
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A lower insulin secretion rate at baseline (1st vs 4th quartile of total insulin secretion during 
OGTT x M/I) was associated with higher blood pressure at year 3 [SBP: 123 ± 14 vs 118 ± 15 
mmHg, p=0.0001; DBP: 78 ± 9 vs 74 ± 9 mmHg, p<0.0001]. A similar inverse association was 
observed for basal insulin secretion at a fixed normal glucose level of 5 mmol/l from the beta-cell 
dose-response [1st vs 4th quartile, SBP: 125 ± 13 vs 116 ± 15 mmHg, p<0.0001; DBP: 79 ± 8 vs 73 
± 9 mmHg, p<0.0001]. 
The incidence of hypertension at year-3 decreased progressively across the quartiles of both total 
insulin secretion and insulin secretion at 5 mmol/l at baseline (Figure 1). Individuals with the lowest 
total insulin secretion rate during OGTT (quartile 1) had a higher incidence of hypertension as 
compared to those with the highest insulin secretion (quartile 4), after adjusting for other baseline 
risk factors (centre, age, gender, physical activity, waist circumference, smoking, alcohol intake, 
fasting glucose, systolic and diastolic blood pressures) [OR: 2.02; 95% CI (1.06, 3.86), p=0.03]. 
Similarly, the inverse association between total insulin secretion rate during the OGTT, 
expressed as a continuous value, and the risk of incident hypertension at 3 years remained 
significant in a multivariable model after controlling for centre, age, gender, physical activity, waist, 
smoking, alcohol intake,systolic and diastolic blood pressure levels at inclusion [OR per 1 SD log 
total insulin secretion: 0.75; 95% CI (0.61, 0.93), p=0.007]. The addition of fasting glucose and 2h 
glucose levels into the model did not alter the significant relationship, [OR: 0.75; 95% CI (0.61, 
0.92), p=0.007] and [OR: 0.75; 95% CI (0.61, 0.93), p=0.007] respectively. 
 
Discussion 
The main finding of this study is that a genetic predisposition to type 2 diabetes and in particular the 
TCF7L2 at-risk allele, was significantly associated with the incidence of hypertension after a 9-year 
follow-up in the general population; TCF7L2 conferred an increased risk of type 2 diabetes, through 
alterations in insulin secretion capacity.  Furthermore, we provide support for the first time, that a 
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lower insulin secretion rate during an OGTT is a risk factor for the development of elevated blood 
pressure in a non-diabetic cohort, even after taking into account insulin resistance, as assessed by 
the gold standard method of the clamp.  
Previous evidence has shown that offspring of patients with type 2 diabetes have an 
increased risk of developing type 2 diabetes, with defects in early beta-cell secretion[22-25]. It has 
also been suggested that these offspring have early autonomic dysfunction, even in the absence of 
glucose intolerance[26], and more often display metabolic abnormalitieswith high insulin levels and 
arterial hypertension[27, 28].In a previous community-based cohort, parental diabetes appeared as 
an independent predictor of longitudinal changes in both systolic and diastolic blood pressures in 
the offspring, regardless of race and gender[29]. Taken together, these observations and our results 
suggest that heritable factors related with type 2 diabetes, increase the risk of various disorders, 
including hypertension.  
Genetic susceptibility totype 2 diabetesseems to be more related to early beta-cell 
dysfunction rather than to insulin resistance [30, 31]. We selected the TCF7L2 polymorphism as 
this variant that has the largest effect on type 2 diabetessusceptibility among the predisposing genes 
discovered to date[10, 32]. To our knowledge, this is the first report to study the longitudinal 
relation of theTCF7L2 genotypeon incident hypertension in the general population. It has been 
demonstrated that the at-risk TCF7L2 genotype is associated with impaired insulin secretion[33] 
and a reduced sensitivity of the beta-cell to incretins[34].The fact that the effect of the TCF7L2 
polymorphism on blood pressure was independent of waist circumference, glycaemia or the insulin-
resistance HOMA2-IR index, underscores the potential role of insulin secretion defects on the 
evolution of blood pressure over time. This is highlighted by our data on the relationship between 
both total and basal insulin secretion and 3-year incident hypertension in the RISC cohort. 
However, we suggest that the association of the TCF7L2 genotype with incident hypertension might 
be related, at least in part, to reduced GLP-1 secretion in these individuals, as recent evidence 
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suggested that incretins may modulate blood pressure [35]. The TCF7L2 variant may then affect 
primarily the incretin levels, and as a consequence, have independent effects on blood pressure and 
on insulin secretion. 
Our longitudinal results are in favor of a positive interaction between subtle elevations in 
glycaemia and genetic predisposition leading to defects in insulin secretion in the development of 
hypertension. Our results are consistent with recent genetic data showing an association between 
the TCF7L2 variant and increased systolic blood pressure in an endogamous ethnic group from 
India [36].However, it should be noted that a recent large GWAS study did not report a significant 
association between the TCF7L2 variant rs7903146 and blood pressure, although a trend was 
observed for systolic blood pressure (p=0.06) and pulse pressure (p=0.04) [37].A regional plot 
around TCF7L2locus from the data publicly available of the ICBP GWAS study suggest that a 
signal near rs7903146may modulate BP, although this variant doesn't appear to be a glycaemic 
signal (data not shown). The differences between our present study and the GWAS report may be 
related to the longitudinal follow-up used in our study as opposed to the case-control design used in 
the GWAS study. Indeed, we did not observe a significant association between the TCF7L2 variant 
and the presence of hypertension in a cross-sectional analysis of the entire D.E.S.I.R. cohort at 
baseline (data not shown). Furthermore, in our study, we found that a large part of the association of 
the TCF7L2 variant with hypertension was observed in people who already had HbA1c at baseline 
above the median value (≥5.7%), which may explain why TCF7L2 locus did not appear as being 
associated with hypertension in large GWAS cross-sectional studies that were not stratified on 
glucose. Our results need to be confirmed in other large prospective cohorts with a long follow-up.  
The causal role of insulin in the development of hypertension has been much debated. It has 
been proposed that insulin resistance and/or hyperinsulinaemia promote the development of 
elevated blood pressure over time [5, 6, 38, 39] with a positive association between insulin levels 
and incident hypertension [39, 40]. In these studies, the insulin secretion rate was not specifically 
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assessed. Our findings confirm an association between fasting insulinaemia and blood pressure but 
however suggest a greater role for reduced insulin secretion in the pathogenesis of hypertension. 
Fasting insulin is a marker of insulin resistance which could be confounded by the presence of 
subtle defects in insulin secretion.  
To our knowledge, the effects of insulin secretion on blood pressure evolution have not been 
investigated previously, in contrast to the role of insulin resistance.In the present study, we found 
that a lower total insulin secretion rate was significantly associated with the incidence of 
hypertension in non-diabetic people, and that this effect was independent of insulin sensitivity. This 
observation was confirmed when we assessed basal insulin secretion at a fixed normal glucose level 
of 5 mmol/l glucose, from the beta-cell dose-response. Interestingly, in the present study, the 
inverse association between insulin secretion and incident hypertension was not related to weight 
gain over the follow-up (data not shown) and was also independent of insulin resistance, as assessed 
by the gold-standard method of the clamp, suggesting alternative mechanisms.  
Potential mechanisms that may explain the increase in hypertension risk with a reduced 
insulin secretion rate, may be the protective action exerted by insulin on the blood vessel. 
Hemodynamic actions of insulin have been suggested [41] and a small blood-pressure lowering 
effect of insulin has been described in non-diabetic individuals [42]. Furthermore, a partial or 
complete deficiency in the insulin receptor and/or the insulin-receptor substrate-1 in the endothelial 
cells, is associated in mice, with endothelial dysfunction and increased blood pressure [43, 44]. 
Together these findings suggest that a reduced activation of the insulin pathway through diminished 
insulin secretion capacity, particularly in the presence of insulin resistance, may lead to endothelial 
dysfunction that favors the development of hypertension. Hyperinsulinaemia has to be interpreted 
as a compensation for enhanced insulin resistance. If this compensation is insufficient, the net effect 
at the cellularlevel, including probably the endothelium, is a down-tuned insulin signal.  
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Furthermore, recent evidence suggests that improving insulin secretion via the modulation 
of incretin concentrations may lower blood pressure, even in non-diabetic hypertensive individuals 
[45, 46]. 
In parallel, subtle defects in beta cell function may facilitate development of hypertension 
through possible repeated post-prandial elevations in glucose levels over time. Glycemic variability 
may contribute to increase blood pressure through chronic induction of inflammation and enhanced 
oxidative stress [47, 48]. Oxidative stress has been shown to correlate with both glycemic 
fluctuations and blood pressure variability, suggesting possible alternative mechanisms to explain 
the increased incidence of hypertension in relation to subtle defects in beta cell function [49]. In 
addition, the STOP-NIDDMtrial has shown that acarbose treatment, which reduces postprandial 
hyperglycemia, was associated with a significant reduction in the development of incident 
hypertensionin those with impaired glucose tolerance, suggesting an impact of postprandial 
excursions on blood pressure [50].This point needs to be specifically investigated in another 
prospective study with ambulatory, continuous assessment of glucose values.  
 
Limitations of the present study include the absence of accurate measures of both insulin 
resistanceand beta cell function over time in the D.E.S.I.R. cohort, which precludes us from 
demonstrating that the association between parental history, the TCF7L2genotype and incident 
hypertension is directly related to defects in beta cell function. It is possible that the association 
observed between parental history and hypertension may be related, at least in part, to enhanced 
insulin resistance in the parents.The number of individuals with the at-risk TCF7L2genotype was 
limited, in comparison with large genetic consortium studies and our results, albeit being 
significant, need to be replicated in other populations. Furthermore, the absence of postprandial 
glucose levels did not allow us to investigate the exact role of this genotype on the development of 
elevated blood pressure. The strengths of the present study are the use of two complimentary 
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cohorts specifically dedicated to the study of glucose metabolism, with a large number of 
normotensive participants at inclusion, aligned laboratory assays, continuous quality control of data. 
The RISC cohort is the largest cohort available with both a systematic evaluation of insulin 
secretion and gold standard measures of insulin sensitivity by the glucose clamp technique, which 
provided the opportunity to clarify the role of alterations of insulin secretion in hypertension. For 
this important question to be addressed, a large number of individuals with high quality measures of 
glucose metabolism is required. 
In conclusion, our study shows that a parental history of type 2 diabetes and at-risk variants 
in the TCF7L2genotype predispose to incident hypertension. The novel finding of the association 
between reduced insulin secretion and the development of elevated blood pressure deserves further 
investigations with the study of the impact of treatments targeting insulin secretion and postprandial 
hyperglycemia on blood pressure. Our results suggest that defects in insulin secretion may be a new 
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Table 1. Baseline characteristics of participants in the D.E.S.I.R. cohort according to incident 
hypertension (HTA) over the 9-year follow-up. 
 Without incident 
HTA 
With incident  
HTA 
P 
 n=1646 n=745  
Age (years) 44  ± 9 49 (9) 0.0001 
Men (%) 41% 52% 0.0001 
BMI (kg/m2) 23.4  ± 3.0 24.8  ± 3.3 0.0001 
Waist circumference (cm) 78  ± 10 84  ± 10 0.0001 
Smoking 21% 20% 0.4 
Systolic blood pressure (mmHg) 121 ± 9 127 ± 7 0.0001 
Diastolic blood pressure (mmHg) 75 ± 7 78 ± 6 0.0001 
Fasting glucose (mmol/l) 5.17  ± 0.55 5.41  ± 0.88  0.0001 
HbA1c (%) 5.35  ± 0.40 5.50  ± 0.55 0.0001 
HbA1c (mmol/mol) 33.2 ± 2.48 34.1 ± 3.41 0.0001 
Fasting insulin (pmol/l) * 39.9 (20.8) 45.3 (23.3) 0.0001 
HOMA2-IR* 1.55 (0.91) 1.29 (0.73) 0.0001 
HOMA2%B* 83.6 (25.7) 82.5 (25.2) 0.3 
 
Data shown are as mean (standard deviation), median (interquartile range) or % 
* log transformation for statistical analysis 




Table 2. Association between parental history of diabetes and incident hypertension in the 
D.E.S.I.R. cohort 
 
 OR (95% CI) P 
Unadjusted 1.30 (1.04-1.64) 0.02 
Adjusted for gender, age 1.45 (1.14-1.84) 0.003 
Adjusted for gender,  1.41 (1.10-1.80) 0.006 
Adjusted for gender, age, waist 1.41 (1.11-1.81) 0.006 
Adjusted for gender, age, waist, HbA1c 1.40 (1.09-1.79) 0.008 
Adjusted for gender, age, waist, fasting glucose, fasting insulin 1.37 (1.07-1.76)  0.01 
Adjusted for gender, age, waist, mean BP, smoking, HOMA-IR 1.37 (1.06-1.77) 0.02 
Adjusted for gender, age, waist, fasting glucose, mean BP, 
smoking, alcohol intake 1.39 (1.04-1.86) 
 
0.03 
Adjusted for gender, age, waist, mean BP, smoking, alcohol 
intake, HOMA-IR 
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Table 3. Association between TCF7L2at-risk variants and incident hypertension (CT+TT vs 
CC as reference) in the D.E.S.I.R. cohort 
 
 OR (95% CI) P 
Unadjusted 1.15 (0.96-1.36) 0.12 
Adjusted for gender, age 1.23 (1.02-1.47) 0.03 
Adjusted for gender, age, BMI 1.22 (1.02-1.47) 0.03 
Adjusted for gender, age, waist 1.22 (1.01-1.47) 0.03 
Adjusted for gender, age, waist, HbA1c 1.22 (1.02-1.47) 0.03 
Adjusted for gender, age, waist, fasting glucose, fasting insulin 1.22 (1.01-1.47) 0.03 
Adjusted for gender, age, waist, mean BP, smoking, HOMA-IR 1.31 (1.08-1.59) 0.006 
Adjusted for gender, age, waist, fasting glucose, mean BP, 





Adjusted for gender, age, waist, mean BP, smoking, alcohol 
intake, HOMA-IR 
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Table 4. Baseline characteristics in the RISC cohort according to incident hypertension 
(HTA) over the 3-year follow-up 
 
 Without incident 
HTA 
With incident  
HTA P (n=881) (n=166) 
Age (years) 43.9 ±8.2 47.7 ±8.1 <0.0001 
Waist (cm) 86 ±12 92 ±12 <0.0001 
BMI (kg/m²) 25.1 ±3.7 27.2 ±4.3 <0.0001 
Smoker (%) 26.3 26.7 0.92 
Physically inactive (%) 19.3 22.0 0.43 
Systolic blood pressure (mmHg) 116 ±12 128 ±10 <0.0001 
Diastolic blood pressure (mmHg) 74 ±8 80 ±7 <0.0001 
Fasting glucose (mmol/L) 5.1 ±0.5 5.3 ±0.6 <0.0001 
2hr glucose (mmol/l) 6.1 ±1.7 5.7 ±1.5 0.02 
Fasting insulin (pmol/l)* 29.5 (21.0) 36.0 (25.7) <0.0001 
Clamp Insulin Sensitivity (M/I) * 134 (88) 114 (76) <0.0001 
Total insulin secretion x M/I* 50.8 (29.7) 46.2 (25.8) 0.0005 
Insulin secretion at 5 mmol x M/I* 90.0 (72.7) 74.2 (71.5) 0.002 
Data shown are as mean ± standard deviation, median (interquartile range) or n  
*log-transformed for analysis 
 Total insulin secretion during the OGTT at baseline, and insulin secretion at 5 mmol/l are both 
expressed in relation to the M/I value (nmol m-2mol min-1kgffm-1 nmol-1) and multiplied by 10-2 
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Legends for figure 
 
Fig.1Incidence of hypertension at year-3 according to the quartiles of (A) total insulin secretion rate 
x M/I during the OGTT (B) basal insulin secretion rate at 5 mmol glucose x M/I at inclusion in the 
RISC cohort. The p value is for trend.
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